**FINANCIAL RELATIONSHIP DISCLOSURE FORM**

As a jointly accredited provider by the ACCME, ANCC, and ACPE, i3 Health has been selected as the official accrediting company by the 11th World Glaucoma Congress Organizers.

i3 Health must ensure balance, independence, objectivity and scientific rigor in all its directly or jointly provided educational activities. Any person who is in a position to influence or control the content of an accredited activity is required to disclose all financial relationships with ineligible companies1 occurring within the past 24 months. Relevant relationships identified on the disclosure form (including the absence of such relationships) must be conveyed to the audience prior to the activity.

|  |  |
| --- | --- |
| Activity Title: | 11th World Glaucoma Congress |
| i3 Health Project ID: | WGC2025 |
| Faculty Name: | Prof. Dr. med. Norbert Pfeiffer |
| Faculty Affiliation: | University Medical Center Mainz – Professor for Ophthalmology |
| Faculty Email: | Norbert.pfeiffer@unimedizin-mainz.de |
| Faculty Role: | Speaker |

Roles: Planning Committee Member; Activity Director; Presenter/Speaker; Nurse Planner; Author; Content Expert; Reviewer; Other (specify role)

**DISCLOSURE**

No, I have no financial relationships with ineligible companies to disclose.

Yes, I have a personal financial relationship with an ineligible company:

| **Nature of Relevant Financial Relationship** | **Ineligible Company1** |
| --- | --- |
| Advisory Board or Panel | ABBVIE, AERIE, ALCON, ALLERGAN, BAYER, BOEHRINGER, ESSENTIAL PHARMA, FOCUS, GATE GROUP, GUIDEPOINT, INTER-REACH, EYESTAR MEDICAL, MEDSCAPE, NICOX, NOVALIQU, NOVARTIS, QULARIS, ROCHE, SANOFI, SANTEN, ZEISS |
| Speaker’s Bureau | ABBVIE, ALCON, ALLERGAN, BAYER |
| Consultant | ABBVIE, AERIE, ALCON, ALLERGAN, BAYER, BOEHRINGER, ESSENTIAL PHARMA, FOCUS, GATE GROUP, GUIDEPOINT, INTER-REACH, EYESTAR MEDICAL, MEDSCAPE, NICOX, NOVALIQU, NOVARTIS, QULARIS, ROCHE, SANOFI, SANTEN, ZEISS |
| Grants/Research Support2 | 3M, ABBVIE, ALCON, ALIMERA SCIENCES, ARANDAL, BAUSCH&LOMB, BAYER HEALTH, BAYER VITAL, BON OPTIC, CHIESI, DORC, EBIGA, ELIOS VISION, ESSILOR, F. AD. MÜLLER, FCI, FIDUS, GEBAUER MEDIZINTECHNIK, GEUDER, GLAUKOS, GSK, HAAG STREIT, HOYA, HUMAN OPTICS, i. com-medical, IRIS EYE GMBH, JOHNSON&JOHNSON, KOWA, MLASE AG, MST, NOVAEYE medical, NOVARTIS, OCULENTIS, OCULUS, OMNIVISION, OPHTEC, ORAYA, PIROPLAST, POLYTECH, PRICON, REINECKERVISION, ROCHE PHARMA, RUCK, SANTEN, SOLVERTUM, TELEON SURGICAL, THEA, TRB CHEMEDICA, TRUSETAL, URSAPHARM, VISUFARMA, W20, ZEISS, ZEISS-AGENTUR, BOEHRINGER, HEIDELBERG ENGINEERING, EYESTAR MEDICAL, IVANTIS, ROCHE |
| Other Financial or Material Support (royalties, patents, etc.) | 3M, ABBVIE, ALCON, ALIMERA SCIENCES, ARANDAL, BAUSCH&LOMB, BAYER HEALTH, BAYER VITAL, BON OPTIC, CHIESI, DORC, EBIGA, ELIOS VISION, ESSILOR, F. AD. MÜLLER, FCI, FIDUS, GEBAUER MEDIZINTECHNIK, GEUDER, GLAUKOS, GSK, HAAG STREIT, HOYA, HUMAN OPTICS, i. com-medical, IRIS EYE GMBH, JOHNSON&JOHNSON, KOWA, MLASE AG, MST, NOVAEYE medical, NOVARTIS, OCULENTIS, OCULUS, OMNIVISION, OPHTEC, ORAYA, PIROPLAST, POLYTECH, PRICON, REINECKERVISION, ROCHE PHARMA, RUCK, SANTEN, SOLVERTUM, TELEON SURGICAL, THEA, TRB CHEMEDICA, TRUSETAL, URSAPHARM, VISUFARMA, W20, ZEISS, ZEISS-AGENTUR, BOEHRINGER, HEIDELBERG ENGINEERING, EYESTAR MEDICAL, IVANTIS, ROCHE |
| Other Conflict with the Presentation Material | Enter here the name of the company |
| Salary/Contractual Services | Enter here the name of the company |
| Stock/Shareholder (excluding diversified mutual funds) | M-LAB |

1 The ACCME defines an “ineligible company” as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies - unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company. For more information, visit [www.accme.org](http://www.accme.org).

2 Only include research funds received directly from industry; grants to your institution are reportable only when you’re the person or named investigator on the grant.

**Speaker/planner declaration**

I attest to the following:

1. Relationships/affiliations will not bias or otherwise influence my involvement in the accredited educational activity;
2. Practice recommendations that are relevant to the companies with whom I have relationships/affiliations will be supported by the best available evidence or absent evidence will be consistent with generally accepted medical practice;
3. All reasonable clinical alternatives will be discussed when making practice recommendations.

I agree to:

1. Submit my presentation to the CME office no later than three weeks in advance of the program to allow for appropriate peer review and duplication in the course syllabus.
2. Avoid the use of trade names in my presentation. If I determine that it is important to clarify via the use of trade names, trade names from all available companies should be included, not just trade names from a single company.
3. If requested, provide appropriate peer-reviewed journal references which support clinical or practice recommendations.
4. Disclose to the program audience when products/services are not labeled for the use under discussion or when the products are still under investigation.
5. Comply with patient confidentiality requirements as outlined in the Health Insurance Portability and Accountability Act (HIPAA)
6. Ensure that use and reproduction of the materials or information used in my presentation will not violate any third party’s copyrights or other property rights. To the extent that copyrighted or trade secret materials are used, reproduced, or displayed within my presentation, I have obtained written permission to use, reproduce, and distribute such materials from the copyright owner. (Please note that the author of an article is not necessarily the copyright holder of the article.)
7. Allow my handout materials/slide set to be distributed electronically to program participants. Distribution may include email, CD, flash drive, and/or download from a website or mobile app.



|  |  |  |
| --- | --- | --- |
| Write here your name and upload your signature |  | 16.06.2025 |

Signature Date

Return Form to: **World Glaucoma Congress 2025**

**Congress Organizers**

**Email: wgc@mci-group.com**

|  |  |  |
| --- | --- | --- |
|  |  |  |

i3 Health Reviewer Signature Date